{'fraction_non_alphanumeric': 0.051969823973176864, 'fraction_numerical': 0.038558256496227995, 'mean_word_length': 4.502304147465438, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Limited Prognostic Value of SUVmax Measured by F-18 FDG PET/CT in Newly Diagnosed Small Cell Lung Cancer Patients

Background: The purpose of this study was to evaluate the prognostic value of the maximum standard uptake value (SUVmax) measured by 18-F fluoro-2-deoxy-d-glucose (F-18 FDG) positron emission tomography/computed tomography (PET/CT) in newly diagnosed small cell lung cancer (SCLC) patients. Methods: We reviewed the medical records of newly diagnosed SCLC patients who were given a histological diagnosis from June 2008 to June 2014. 82 patients who satisfied the inclusion criteria were enrolled for final analysis (male n = 75, female n = 7). The relationship between SUVmax and overall survival (OS) and progression-free survival (PFS) was evaluated. Results: Median follow-up was 25.0 months (range 11.6-55.5 months). The median OS was 11.2 months (range 1.6-55.5 months), and the median PFS was 6.1 months (range 0.9-55.5 months). Survival analysis showed no statistical differences in OS and PFS between high and low SUVmax groups. Conclusion: This study does not support the use of SUVmax of pretreatment F-18 FDG PET/CT scans as a prognostic tool for patients with SCLC.